Legal & General Group
KALV

Legal & General Group’s KalVista Pharmaceuticals KALV Stock Holding History

Legal & General Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$399K Sell
19,787
-4,031
-17% -$65K ﹤0.01% 2414
2025
Q4 		$385K Sell
23,818
-136
-0.6% -$1.8K ﹤0.01% 2485
2025
Q3 		$292K Buy
23,954
+19,752
+470% +$273K ﹤0.01% 2555
2025
Q2 		$47.5K Sell
4,202
-4,338
-51% -$53K ﹤0.01% 2717
2025
Q1 		$98.6K Buy
8,540
+396
+5% +$4.04K ﹤0.01% 2668
2024
Q4 		$69K Buy
8,144
+1,494
+22% +$15.5K ﹤0.01% 2747
2024
Q3 		$77.1K Buy
6,650
+270
+4% +$3.4K ﹤0.01% 2746
2024
Q2 		$75.2K Buy
6,380
+3,784
+146% +$44.2K ﹤0.01% 2757
2024
Q1 		$30.8K Hold
2,596
– – ﹤0.01% 2848
2023
Q4 		$31.8K Buy
2,596
+644
+33% +$5.86K ﹤0.01% 2883
2023
Q3 		$18.8K Sell
1,952
-405
-17% -$4.14K ﹤0.01% 3060
2023
Q2 		$21.2K Hold
2,357
– – ﹤0.01% 3093
2023
Q1 		$18.5K Hold
2,357
– – ﹤0.01% 3085
2022
Q4 		$15.9K Hold
2,357
– – ﹤0.01% 3197
2022
Q3 		$34K Buy
2,357
+304
+15% +$4.25K ﹤0.01% 3065
2022
Q2 		$20K Sell
2,053
-720
-26% -$7.94K ﹤0.01% 3237
2022
Q1 		$40K Hold
2,773
– – ﹤0.01% 3042
2021
Q4 		$37K Buy
2,773
+321
+13% +$5.11K ﹤0.01% 3098
2021
Q3 		$42K Hold
2,452
– – ﹤0.01% 3025
2021
Q2 		$59K Buy
2,452
+786
+47% +$20.6K ﹤0.01% 2899
2021
Q1 		$43K Buy
1,666
+348
+26% +$9.14K ﹤0.01% 2858
2020
Q4 		$25K Hold
1,318
– – ﹤0.01% 3002
2020
Q3 		$17K Sell
1,318
-418
-24% -$5.23K ﹤0.01% 3026
2020
Q2 		$21K Sell
1,736
-363
-17% -$3.86K ﹤0.01% 3051
2020
Q1 		$16K Sell
2,099
-323
-13% -$4.36K ﹤0.01% 2993
2019
Q4 		$40K Buy
2,422
+478
+25% +$6.24K ﹤0.01% 2905
2019
Q3 		$23K Hold
1,944
– – ﹤0.01% 3086
2019
Q2 		$43K Buy
+1,944
New +$45.6K ﹤0.01% 2832

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's KALV Position: Q1 2026 in Review

Legal & General Group reduced its KalVista Pharmaceuticals (KALV) stake by 17% in Q1 2026, selling an estimated $65K and leaving 19,787 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #2414.

Legal & General Group first reported a position in KALV in Q2 2019 and has held it in 28 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Legal & General Group held 19,787 shares of KalVista Pharmaceuticals worth $399K as of Q1 2026.
  • Legal & General Group sold 4,031 KalVista Pharmaceuticals shares in Q1 2026, an estimated $65K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2414 holding.
  • Legal & General Group first reported a position in KalVista Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.